Imunon appoints Curis CEO James E. Dentzer to board effective Sept 29, 2022

Imunon, Inc.

James E. Dentzer appointed as Class II director; board expands to nine members.
Dentzer is President & CEO of Curis, Inc., with over 20 years of biopharma financial leadership.
Receives standard non-employee director compensation plus initial option grant for 2,667 shares vesting over three years.
Board determined Dentzer is independent under SEC and NASDAQ rules.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

James E. Dentzer

Class II Director

IMNN · Imunon, Inc.

Effective: 2022-09-29
Filed: October 3, 2022, 7:59 PM ET

On October 3, 2022, Imunon, Inc. (the “Company”) announced that the Board of Directors (the “Board”) appointed James E. Dentzer to the Board as a Class II Director effective September 29, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

James E. Dentzer was appointed as Class II Director at Imunon, Inc..

Action: appointed
Role: Class II Director

Exact text from the filing

On October 3, 2022, Imunon, Inc. (the “Company”) announced that the Board of Directors (the “Board”) appointed James E. Dentzer to the Board as a Class II Director effective September 29, 2022.

View on SEC.gov

Imunon, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-027459

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.